A child in a Chinese classroom puts on a soft band with a few sensors, and a teacher's screen lights up with a number: how focused is this student, right now, according to their brainwaves? A few years ago that scene sparked a privacy outcry. Today the same company behind it is preparing to list on the Hong Kong stock exchange.
BrainCo (强脑科技) is not a lab experiment. It is one of the rare brain–computer interface (脑机接口) companies that crossed from prototype to factory floor — and then to a capital-markets queue.
From a Harvard basement to Hangzhou
BrainCo was founded in 2015 by Bicheng Han (韩璧丞), then a PhD candidate at Harvard University's Center for Brain Science, and was incubated at the Harvard Innovation Labs. In 2018 the company moved its headquarters to Hangzhou, Zhejiang, while keeping a US office in Somerville, Massachusetts.
Its bet was on non-invasive BCI — reading brain signals through the scalp with EEG (electroencephalography) rather than implanting electrodes. That choice trades signal richness for safety and scalability, and it is what made a consumer product possible.
The headband that actually shipped
The flagship consumer line is Focus, an EEG headband that measures attention and, in later versions, helps with relaxation and sleep. The first version, Focus 1, was shown in 2016; it was later rebranded toward wellness as FocusCalm and FocusZen (正念舒压).
The milestone that separates BrainCo from most BCI startups is volume. In January 2022, the company held a ceremony for the 100,000th unit of its second-generation wearable EEG device rolling off the line — reported by China Daily as the world's first high-precision BCI product to reach six-figure mass production. BrainCo describes that as proof the engineering problems of portable, low-noise bio-signal capture had been solved well enough to sell.
The headband has shown up in three very different places:
- Classrooms in China, as "Focus EDU," where teachers tracked group attention — a use that drew criticism in 2019 over student surveillance and was reportedly pulled from school trials.
- Elite sports, where athletes used EEG feedback to train focus and manage stress.
- Wellness and sleep, through spin-off products like Easleep and the meditation system Zentopia.
The money and the listing
BrainCo is frequently called China's first BCI unicorn. In January 2026 it closed a financing round of roughly 2 billion RMB (≈ US$280 million / HK$2.18 billion), co-led by IDG Capital and Walden International, at a post-money valuation reported above US$1.3 billion (about HK$10 billion). Around the same time it filed confidentially for an initial public offering on the Hong Kong Stock Exchange, working with China International Capital Corporation and UBS, according to multiple financial-news reports.
That would make BrainCo one of the first Chinese neurotechnology firms to reach public markets, and a member of Hangzhou's so-called "Six Little Dragons" (六小龙) — the city's breakout AI and robotics startups that also include DeepSeek and Unitree.
Why a headband matters in the BCI race
Most of the headline BCI drama is invasive: Neuralink's implants, China's Beinao-1 (北脑一号) speech decoder, surgical electrodes. Those are medically profound but slow to reach ordinary people. BrainCo's quieter achievement is the opposite — a consumer-grade, non-invasive device that already exists in six figures of units.
That matters because the BCI field has a commercialization gap. High-end implants may restore speech to a locked-in patient, but they will not appear in homes by the million. A wearable EEG headband, whatever its limits, is the version of neurotechnology a shopper can actually buy today.
What readers should keep in mind
The headband does not read thoughts. It infers a narrow signal — attention or relaxation state — from scalp electrical activity, which is noisy and easy to game. The classroom episode is the cautionary tale: the same sensor that helps one child focus can become a surveillance tool if deployed carelessly. BrainCo has since reframed Focus as a personal wellness and training aid rather than an institutional monitoring device.
What readers can do now
- If you buy consumer neurotech, treat an EEG headband as a feedback trainer, not a medical device. Its value is in making focus or calm measurable, not in diagnosing anything.
- If you follow BCI markets, watch BrainCo's Hong Kong filing as a test of whether non-invasive consumer BCI can sustain a public-company valuation — the invasive players are still pre-revenue.
- If you build education products, study the 2019 schools controversy as a privacy case study; attention data on minors is a governance landmine, not a feature.
Honest limitations
Verified facts: BrainCo founded 2015 by Bicheng Han at Harvard Innovation Labs, HQ moved to Hangzhou in 2018 — from Wikipedia and Securities Times (证券时报). The 100,000-unit mass-production milestone (January 2022) is reported by China Daily based on a company announcement, not an independent audit, and should be read as the company's own claim. The January 2026 financing of ~2 billion RMB (≈ US$280M / HK$2.18B) and confidential HK IPO filing with CICC and UBS are reported by Securities Times, Caproasia, Tencent News, and BigGo Finance; valuation is cited between US$1.3B and US$1.8B across sources, so "above US$1.3 billion" is the conservative floor. BrainCo is part of Hangzhou's "Six Little Dragons." The product line (Focus 1 / FocusCalm / FocusZen / Easleep) and the 2019 school-surveillance controversy are documented in Wikipedia and BBC/EDU coverage. The IPO is filed, not completed; no listing date is confirmed. This article contains no investment advice, and analysis is current to 28 September 2026.